David M. Foureau, PhD of Levine Cancer Institute discusses how targeting T-cells in myeloma may be the new focus for clinical trials at the 58th ASH Annual Meeting in San Diego, CA.
David M. Foureau, PhD of Levine Cancer Institute discusses how targeting T-cells in myeloma may be the new focus for clinical trials at the 58th ASH Annual Meeting in San Diego, CA.